Cannabis Law Report

JULY 31, 2019

The New York cannabis market size is expected to reach USD 7.07 billion by 2025, according to a new report by Grand View Research, Inc., Cannabis sales are increasing due to its medical benefits, especially in the treatment of ailments such as chronic pain, mental disorders, and cancer. Grandview research writes.

Chronic Pain 40

Chronic Pain Epilepsy Treatment Recreational 40

Cannabis Law Report

JANUARY 12, 2020

It has approved use of cannabis extracts for treatment of a range of illnesses and conditions, including cancer, epilepsy, Alzheimer’s, Parkinson’s disease and anxiety. The Government has promised to open more clinics in greater Bangkok, with patients able to book appointments via a specialised smartphone app.

Research and Development 59

Research and Development Marijuana Agriculture Medicine 59

Cannabis Law Report

JULY 26, 2019

Amidst the contemplation on the growth of the medicinal cannabis space in Australia, the legalisation of medicinal cannabis is expected to contribute approximately $8.5 Used for recreational and medicinal purposes, cannabis has been a debatable product since time immemorial. Cannabis in the Aussie Land.

Banking 45

Banking Medicine Research and Development Recreational 45

Cannabis Law Report

FEBRUARY 18, 2020

Even though 47 states have legalized cannabis for some forms of medical use , New York significantly falls behind its neighbors in terms of marijuana legislation. Marijuana remained illegal, however, until 1977, when the possession of 25 grams or less of cannabis was decriminalized. for decades.

Marijuana 59

Marijuana Consumption Dispensary Vaping 59

Cannabis Law Report

JANUARY 5, 2022

This patent issuance is rewarding and timely as we launch our Phase 2 trial of MYMD-1 as a therapy for sarcopenia, frailty, and aging, which is currently recruiting patients,” said Chris Chapman, M.D., The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

NOVEMBER 16, 2021

The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. The market for treating aging disorders and extending healthy lifespan is expected to be at least $600 billion by 2025 1 according to a major investment bank.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 20, 2019

PUBLISHER: CANNABIS LAW REPORT. It is also the first FDA approved drug for the treatment of patients with Dravet syndrome. Big Pharma companies want botanical marijuana to remain illegal because it is financially beneficial to them, not because synthetic marijuana is decidedly better for patients.” Author Biography.

Marijuana 45

Marijuana Pharmaceutical Chronic Pain Research and Development 45